Category: Technology Licenses
Created On: 2022-04-28
Record Count: 14
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 28248
The Hedgehog signaling pathway transmits information to embryonic cells required for proper development.
The Hedgehog pathway is normally active during embryonic development and regulates tissue and organ formation by directly promoting cell division in specific cell types, and by activating other secondary signaling pathways that control the synthesis of growth promoting and angiogenic (blood vessel-forming) factors. Unregulated activation of the Hedgehog pathway is believed to play a central role in allowing the proliferation and survival of cancer cells and leading to formation and maintenance of certain cancers, including BCC and medulloblastoma as well as colorectal, ovarian, pancreatic, small cell lung and breast cancers, among others.
IPSCIO Record ID: 207259
The License granted by Licensor for Licensee Products, upon the earliest to occur of a Licensors Early Termination Notification, the occurrence of a Mandatory Termination, and the termination of the Research Phase, Licensor shall grant an exclusive license, under the Licensor Intellectual Property Rights and rights in and to the Collaboration Technology, excluding Licensors rights in Licensor Gene Therapy Technology, to develop, make, have made, import, use, have used, offer to sell, sell, and have sold Licensee Products in and outside the Field within the Territory.
For the License granted by Licensor Outside the Field, Commencing on the Effective Date, Licensor grants an exclusive license in the Territory, with the right to grant sublicenses to develop, make, have made, import, use, have used, offer to sell, sell and have sold outside the Field products that comprise a Hedgehog-basedMolecular Entity.
Licensor grants for Non-Hedgehog Products upon the Effective Date, a non-exclusive license, under Licensors rights in and to the Collaboration Technology, excluding Licensor Gene Therapy Technology, Fundamental Hedgehog Gene Therapy Collaboration Technology and Hedgehog Specific Gene Therapy Collaboration Technology, to practice the Collaboration Technology for the purpose of discovering and developing products that do not comprise a Hedgehog-based Molecular Entity, and make, have made, import, use, have used, offer to sell, sell and have sold in the Territory Ontogeny Non-Hedgehog Products in and outside the Field.
Hedgehog proteins modulate development and patterning of the embryonic nervous system. As expression of desert hedgehog and the hedgehog receptor, patched-1, persist in the postnatal and adult peripheral nerves, the hedgehog pathway may have a role in maturation and maintenance of the peripheral nervous system in normal and disease states.
Neurology therapies based upon the hedgehog proteins are being developed in partnership with Licensor.
IPSCIO Record ID: 230768
– a worldwide Exclusive license to Licensed Patents, in the Licensed Field of Use, to import, make, use, offer for sale, sell, have made, and have sold Licensed Product(s) described;
– a worldwide Exclusive license under Licensed Patents and Licensed Materials to develop, make and have made Developed Product(s) in the Licensed Field of Use; and,
– a worldwide non-exclusive license to Licensed Materials.
Licensed Material means in either singular or plural means those proprietary materials which are Hedgehog genes and proteins encoded by the genes, including Drosophila hedgehog; Sonic hedgehog from mouse, frog, fish; Xenopus Cephalic hedgehog; Xenopus handed hedgehog; Xcnopus Hedgehog 4;
Twhh (Tiggicwinkle Hedgehog), and, Fragments and/or truncated forms of the above genes, including Truncated forms of Banded Hedgehog, including delta N-C & N; Truncated forms of mouse sonic hedgehog; COOH terminal fragments of Drosophila hedgehog; SHH-C terminal fragment, and, Hh Delta 89-254.
The Hedgehog signaling pathway is a signaling pathway that transmits information to embryonic cells required for proper cell differentiation.
IPSCIO Record ID: 203330
For the research license, Licensor grants a non-exclusive, non-sublicensable, but exercisable by a Third Party, license, under the Licensed IP, for internal research purposes other than the discovery of Compounds.
Licensor grants a first right to negotiate pursuant to which Licensor shall notify Licensee in writing if it wishes to license to another party rights to develop and/or commercialize a given Ex Vivo Application; and provide to Licensee all material information related to such Ex Vivo Application that exists and is available to Licensor at the time of such notification.
Licensor grants a first right to negotiate pursuant to which Licensor shall notify Licensee in writing if it wishes to license to another party rights to develop and/or commercialize a given Licensor Compound; identify in such notice the Therapeutic Area in which Licensor is developing, or intends to develop, such Licensor Compound; and provide to Licensee all material information related to such Licensor Compound that exists and is available to Licensor at the time of such notification.
The Licensed Product means any Valid Claim Product, Licensee Modified Product, Know-How Product and/or Non-Collaboration Product, mean a Licensed Product that contains a unique Lead Compound, which includes the salts, solvates, isomers, polymorphs and prodrugs of such Lead Compound. Notwithstanding the foregoing, if Licensor performs Funded Work on any salts, solvates, isomers, polymorphs and/or prodrugs of a given Lead Compound, each new Lead Compound resulting from such Funded Work shall be deemed a unique Lead Compound.
A Valid Claim Product means any formulation of a Lead Compound that is Covered by the Licensed IP; provided, however, Valid Claim Product excludes any Licensee Modified Product; Licensed Product that is Covered by a Licensee Collaboration Patent and is not Covered by either a Licensor Collaboration Patent or a Joint Collaboration Patent; and Non-Collaboration Product.
A Know-How Product means any formulation of a Lead Compound that is not a Valid Claim Product, a Licensee Modified Product, or a Non-Collaboration Product.
If Licensor does not perform Funded Work on such Lead Compound, any formulation of such Lead Compound shall be referred to as a Non-Collaboration Product.
The Compound means any molecule that, as one of its primary mechanisms of therapeutic action, specifically binds to or interacts with at least one component of the Wnt Pathway and/or modulates the signaling of the Wnt Pathway; provided, however, Compound shall exclude any molecule that is or incorporates
– a polypeptide (e.g., an antibody, antibody fragment, peptide, protein) or a nucleic acid (e.g., antisense, RNAi oligos, DNA);
– an antagonist of the Hedgehog Pathway that was tested under the Hedgehog Agreement for activity in modulating the signaling of the Hedgehog Pathway before being tested under this Agreement, in which case, such molecule shall be governed by the Hedgehog Agreement; or
– a molecule that is independently developed by Licensee or in-licensed by Licensee, including as may be subsequently modified by Licensee, from a Third Party, in the case of either, unless Licensee elects, in its sole discretion, by written notice to Licensor at any time while the Licensee License is in effect, to include such molecule as a Compound.
The Wnt Pathway means a signaling pathway activated by any Wnt protein. where the components of such pathway include. but are not limited to, frizzled receptors, B-catenin, Bcl9/legless, CBP, TCF/LEF and Pygopus.
This new collaboration, in which Licensor will work exclusively with Licensee, involves the discovery and development of small molecule modulators of an undisclosed pathway that plays an important role in cell proliferation. This pathway is a key regulator of tissue formation and repair, and its abnormal activation is associated with certain cancers.
IPSCIO Record ID: 203513
Biological Materials shall mean the proprietary materials developed in the laboratories of certain Drs. as a result of research concerning the licensed subject matter, identified including Polypepetides, Gene Sonic hedgehog (shh), Gene Indian hedgehog (lhh) and Gene Desert hedgehog (Dhh), together with any progeny, mutants or derivatives, to the extent that they contain a substantial portion of the original Biological Materials. Proprietary materials shall mean materials which are not generally available from another source and which are under the control of Licensor.
Sonic hedgehog is a protein that in humans is encoded by the SHH ('sonic hedgehog') gene. Both the gene and the protein may also be found notated alternatively as 'Shh'.Sonic hedgehog is one of three proteins in the mammalian signaling pathway family called hedgehog, the others being desert hedgehog (DHH) and Indian hedgehog (IHH). SHH is the best studied ligand of the hedgehog signaling pathway. It plays a key role in regulating vertebrate organogenesis, such as in the growth of digits on limbs and organization of the brain.
Milestone Products shall mean products which are not Licensed Products and are identified or discovered in material part through the use of processes or subject matter covered in a Claim or agonize or antagonize members of the hedgehog gene family or agonize or antagonize follistatin or incorporate a substantial portion of a Biological Material or which could not be made except by utilizing a Biological Material or are antibodies which bind to a hedgehog protein.
PATENT RIGHTS shall mean United States patent application Serial No. 08/136.748 filed October 14. 1993 and United States patent application Serial No. 08/176.427 filed December 30. 1993. United States Patent Application Serial No. 09/394.020. filed September 10,1999.
IPSCIO Record ID: 202861
Licensor grants a non-exclusive license, under Licensors rights in and to the Collaboration Technology, to practice the Collaboration Technology for the purpose of discovering and developing products that do not embody, or are not developed through the use of Technology related to the Vertebrate Hedgehog Family, and make, have made, import, use, have used, offer to sell, sell and have sold Licensee Non-Hedgehog Products in and outside the Field within the Territory
Licensor grants an option to initiate one or more Development Programs.
Licensor possesses proprietary rights to another important family of proteins that induce cell and tissue growth and differentiation, referred to as the hedgehog family. Sonic Hedgehog has neuro-inductive, growth factor and neuroprotective properties, and offers the potential for treatment of neurodegenerative diseases such as peripheral neuropathy (i.e., a loss of nerve function in the extremities of the body), Parkinson's disease, Alzheimer's disease, Amyotrophic Lateral Sclerosis and Multiple Sclerosis. Desert Hedgehog plays a role in normal peripheral nerve signaling. Licensor is exploring its use in disorders related to nerve signaling such as chemotherapy- and diabetes- induced neuropathy.
Neurology therapies based upon the hedgehog proteins are being developed in partnership with the Licensee.
IPSCIO Record ID: 26594
Provisional Patent Application 60/526,538 – Methods of Inhibiting Apoptosis Using Latent TGFβU.S. Provisional Patent Application 60/526,666 – Methods of Identifying of Modulators of Apoptosis From Parasites and Uses Thereof U.S. Provisional Patent Application 60/526,496 – Methods of Inhibiting Apoptosis Using Inducer's of NF-kB U.S. Provisional Patent Application 60/526,667 – Methods of Inhibiting Apoptosis Using Latent TGFβU.S. Provisional Patent Application 60/526,460 – Methods of Protecting Against Radiation Using Inducer's of NF-kB U.S. Provisional Patent Application 60/526,461 – Methods of Protecting Against Radiation Using Flagellin U.S. Provisional Patent Application 60/571,149 – Small Molecules Inhibitors of MRP1 and Other Multi drug Transporters U.S. Provisional Patent Application 60/589,637 – Activation of p53 and Inhibition of NF-kB for cancer treatment.
CBLC100 series small molecules that restore the activity of p53 tumor suppressor in cancers, including renal cell carcinomas, sarcomas, prostate cancers and other types of malignancies; curaxines and derivatives thereof are representative examples of this category;
CBLB101 series substances of biological nature (i.e., cytokine, chemokines and other secreted molecules) and their bioactive derivatives produced by tumor cells and capable of modulating cell survival; TGFÃŸ2 and derivatives thereof and derivatives thereof are representative examples of this category;
CBLB501 series natural factors produced by extracellular parasites and symbiont of humans and other mammalian species and their bioactive derivatives capable of modulating cell survival mechanisms of host cells; flagellin of Salmonella typhimurium and derivatives thereof are representative examples of this category;
CBLC500 series small molecules modulating tumor and normal cell sensitivity to cytotoxic chemicals by altering activity and substrate specificity of multi drug transporters; inhibitors of MRP1 and derivatives thereof are representative examples of this category.
IPSCIO Record ID: 28541
Licensed Patent means U.S. Patent Application, Serial Number 11/078,899.
Stem cells have a capacity both for self-renewal and the generation of differentiated cell types. This pluripotentiality makes stem cells unique. In addition to studying the important normal function of stem cells in the regeneration of tissues, researchers have further sought to exploit the potential of in situ and/or exogenous stem cells for the treatment of a variety of disorders. While early, embryonic stem cells have generated considerable interest, the stem cells resident in adult tissues may also provide an important source of regenerative capacity.
11/078,899 (7,837,993) The regenerative potential of aged stem cells is enhanced by activation of the Notch signaling pathway and/or inhibition of TGF-ÃŸ signaling pathway. Stem cells in aged tissues are capable of proliferation and tissue regeneration, but in their native setting are not provided with the appropriate signals to do so. By administering tissue regenerating agents, organ stem/progenitor cells are provided with the appropriate signals to regenerate the corresponding differentiated tissues.
IPSCIO Record ID: 7387
Recent experiments have led to the identification of a novel source of primary human cells that secrete a factor capable of inhibiting tumor cell growth. Co culture of tumor cell lines with these human cells results in inhibition of proliferation of the tumor cells and ultimate death. Further media conditioned by the primary human cells also inhibits proliferation of the tumor cells lines and death of the cells. The technology consists of methods for isolation and propagation of the primary human cells, gene profiles obtained from the cells identifying candidate micro RNAs and growth factor genes, and methods for generating media conditioned by these cells for isolation of the inhibitory factor(s).
This technology offers the potential to identify molecules that can kill tumor cells and further provides insight into the potential use of cells for delivery of these inhibitory factors in vivio.
IPSCIO Record ID: 256505
Fruquintinib is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, fruquintinib inhibits VEGF-induced phosphorylation of VEGFRs 1, 2, and 3 which may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death. Expression of VEGFRs may be upregulated in a variety of tumor cell types.
IPSCIO Record ID: 356954
an exclusive license, sublicenseable, under the Licensor know-how, solely after the end of the Restriction Period, to research, develop, make, have made, use, sell, offer for sale, and import Compounds in the Field in the Territory.
For the Research License, Licensor grants a perpetual, irrevocable, non-exclusive, non-sublicensable except to Third Party contractors and service providers performing for the benefit of Licensee, license under the Licensor Technology and Licensee Technology to make, import, and use but not to sell or offer for sale Compounds for internal research purposes only.
Licensor grants an option to obtain an exclusive, sublicense from Licensor to certain Patent Rights licensed to Licensor under the Georgia Regents Research Institute License Agreement or Lankcnau Institute for Medical Research License Agreements, to research, develop, make, have made, use, sell, offer for sale and import Compounds and Licensed Products in the Field in certain countries in the Territory.
Licensed Compound means NLG919 or any Next Generation Compound.
NLG919 means Licensorâ€™s proprietary small molecule IDO inhibitor known as of the Execution Date as NLG919, as further described in IND 119045 or any enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug thereof.
Compound means a compound with a molecular weight of two thousand (2,000) Daltons or less], that hinds to and inhibits the activity of one or both of the 100 Target and TDO Target. with an IC50 of 1 ÂµMor less in the applicable Enzymatic Assay, and that is being researched, developed or commercialized to exert its influence through the inhibition of one or both of the IDO Target or TDO Target, including NLG919, but excluding Indoximod.
Enzymatic Assay means, with respect to the IDO Target, the assay described in IND 119045 Document PD0l-MRMP01 1-SP04-E248, and, with respect to the TDO Target. Enzymatic Assay shall also include an alternate means of detecting the products of the enzyme reactions or minor changes in the above enzyme assay protocols, as agreed upon by the JRC. Any IC50s of control compounds measured with an alternate assay format should fall within 3-fold of the assay method.
Indoximod means Licensorâ€™s proprietary small molecule IDO pathway inhibitor known as of the Execution Date as indoximod, or 1-methyl-D-tryptophan, or any, enantiomer, polymorph, salt form, base, acid, racemate, isomer, diastereomer, tautomer, solvate, hydrate, ester or Known Prodrug thereof.
IDO pathway inhibitors are another class of immune check point inhibitors akin to the recently developed antibodies targeting CTLA-4, PD-1, and PD-L1 that represent potential breakthrough approaches to cancer therapy. The IDO pathway regulates immune response by suppressing T-cell activation which enables local tumor immune escape. Recent studies have demonstrated that the IDO pathway is active in many cancers, both within tumor cells as a direct defense against T-cell attack, and also within antigen presenting cells in tumor draining lymph nodes whereby this pathway promotes peripheral tolerance to tumor associated antigens (TAAs). When hijacked by developing cancers in this manner, the IDO pathway may facilitate the survival, growth, invasion and metastasis of malignant cells whose expression of TAAs might otherwise be recognized and attacked by the immune system. NewLink has a number of active programs directed at synthesizing inhibitors to the IDO pathway and additionally has discovered novel tryptophan-2,3-dioxygenase (TDO) specific inhibitors that are potential anti-cancer compounds which could function individually or in combination with IDO inhibition.
Indication means any separately defined. well-categorized class of human disease, syndrome or medical condition for which a separate MAA may be filed with a Regulatory Authority. Each different tumor type or a different hematological malignancy as classified by cell lineage (e.g., acute lymphoblastic leukemia is a different Indication from chronic myclogenous leukemia) shall be a separate Indication; however each different line of therapy for a particular tumor type or hematological malignancy will not he considered a separate Indication.
IPSCIO Record ID: 227271
– the exclusive worldwide license in the Field of Use to use the Patent to manufacture and sell the Product; and,
– the right to grant sublicenses to any Patent licensed exclusively hereunder, provided that any Sublicensee agrees to be bound by the terms and conditions of this Agreement applicable to Sublicensees.
The agreement is exclusive except for the non-exclusive license granted to the U.S. government
Angiogenesis And Tumor Growth In Vivo.
2805 60/114,878 January 6, 1999 Method and Composition for Angiogenesis Inhibition
2806 60/114,877 January 6, 1999 Method and Composition for Angiogenesis Inhibition
2908 60/143,581 July 13, 1999 Generation And Use Of Mab FM155 To Inhibit Angiogenesis and Tumor Growth
2909 60/143,534 July 13, 1999 'Generation And Use Of MAB XL313 To Inhibit Angiogenesis And Tumor Growth In Vivo
Anti-Angiogenesis for the Treatment of Cancer
In a process known as angiogenesis, cancer cells stimulate the formation of new blood vessels in order to bring oxygen and nutrients to rapidly-growing tumor tissue. The onset of angiogenesis is caused mainly by tumor cell production of growth factors that activate the cells that line the blood vessels. These activated cells begin to divide and lead to the remodeling of the extracellular matrix, which is a dense protein network that provides support and growth signals for blood vessels and tumors.
IPSCIO Record ID: 230770
– during the Research Term, the exclusive worldwide right and license to use the Licensor Technology to the extent necessary to conduct the Research Program;
– during the Evaluation Tail, the exclusive worldwide right and license to use the Licensor Technology to the extent necessary to determine whether any of the then identified Hit Compounds or Activator Compounds can become Lead Compounds and to further screen and conduct selectivity testing of any Lead Compounds identified in the Research Term for the purpose of determining whether Licensee will select any such Lead Compounds as Development Candidates;
– the exclusive right and license to use the Licensor Technology to develop and have developed Agreement Compounds and Products and to make, have made, use, import, export, market, offer for sale, sell and have sold Products in the Territory for use in the Licensee Field; and
– if Licensee exercises the Licensee Option with respect to any Option Compound, the exclusive right and license to use the Licensor Technology to develop and have developed such Option Compound and any Option Product containing such Option Compound and to make, have made, use, import, export, market, offer for sale, sell and have sold such Option Products in the Territory for use in the Licensee Field.
The Product shall mean any final dosage form of a pharmaceutical product containing a Development Compound, independent of indication, route of administration, or dosage strength or form.
Agreement Protein shall mean the Hedgehog protein,as described in U.S. Patent #6,384,192, and any proteins and polypeptides, included in the Licensor Technology, which have preferential binding affinity foe the Hedgehog proteins natural receptor.
Compound shall mean a small molecule or macromolecule compound (including. without limitation, the Agreement Protein), together with all complexes, mixtures and other combinations, pro~drugs, metabolites, enantiomers, salt forms, racemates and isomers thereof.
Licensors Field shall mean the topical administration of Activator Compounds or Agreement Protein for the promotion of hair growth and the Local Administration of Activator Compounds for the treatment of cardiovascular diseases, including but not limited to the use of an Activator Compound coated on a cardiovascular stent.
Licensees Field shall mean the treatment or prevention of diseases and/or disorders in humans.
The Research Field means the discovery, characterization, design, development and commercialization of Compounds for the treatment or prevention of neurodegenerative diseases or conditions and/or neuropathies wherein such Compounds exert such therapeutic, prophylactic or other beneficial effects are achieved, in whole or in material part, through Pathway Activator Activity.
IPSCIO Record ID: 27004
Licensee recognizes the contribution of the Company in assisting Licensee in this process.
Royalties shall be paid for 10 years from the date of first commercial sale by Licensee of each such Cancer Therapeutant Product in each country of the world, on a country by country basis.
Update from 10K filed 2/20/1996 In April 1986, Licensee and the Company entered into a collaborative research agreement and several other related agreements. During the first five years of the collaboration, the Company and Licensee focused principally on understanding the molecular biology of oncogenes. In 1991, Licensee and the Company renewed the collaboration for a new five-year term and expanded the resources and scope of the collaboration to focus on the discovery and development of cancer therapeutic products that target oncogenes and anti-oncogenes. Oncogenes play a key role in the conversion of normal cells to a cancerous state. Anti-oncogenes, or tumor suppressor genes, encode proteins that generally function to block the proliferative growth of particular cell types. A loss of function of certain tumor suppressor genes can result in uncontrolled cell growth.
Currently, the Company's collaboration with Licensee focuses on discovering compounds that act upon eight target proteins involved in cancer. The Company's screening program has resulted in the identification of a proprietary lead compound that inhibits a protein associated with a number of major cancers. Licensee is currently conducting pre-IND safety and toxicity studies on this compound. If such studies are successful, the Company expects that Licensee may file an IND as early as the second half of 1996. The success of such studies and the continued development of this compound depends on several factors outside the control of the Company, including the amount and timing of resources devoted by Licensee and the successful optimization of the compound. There can be no assurance that this schedule will be met or that an IND for this lead compound will be filed.
All patent rights and patentable inventions derived from the research under this collaboration are owned jointly by the Company and Licensee. The Company is obligated to file, prosecute and maintain such patents. The Company has granted Licensee an exclusive, worldwide license to make, use, and sell the therapeutic products resulting from this collaboration in exchange for royalty payments. This license terminates on the date of the last to expire of the Company's relevant patent rights.